Home | Current Issue | Past Issues | Search | CollectionsRSS | PDA Services | FAQ | SHCIM Online | Chinese Updated Saturday, July 21, 2018
Submit a manuscript
Send response
Read responses
Advance online publication
Sign up for e-alert
JCIM job opportunities
Contact JCIM
 Information For
 About JCIM
Journal description
Editorial policy
Privacy policy
Copy right
Editorial staff
 Language Polishing
Journal of Chinese Integrative Medicine: 2017; 15(2): 77–87
DOI: 10.1016/S2095-4964(17)60313-3
Potential application of the Kampo medicine goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy
1. Marco Cascella (Division of Anesthesia, Department of Anesthesia and Pain Medicine, Istituto Nazionale Tumori “Fondazione G. Pascale”—IRCCS, via Mariano Semmola, Naples 80131, Italy )
2. Maria Rosaria Muzio (Division of Infantile Neuropsychiatry, UOMI-Maternal and Infant Health, Asl NA 3 SUD, Torre del Greco, via Marconi, Naples 80059, Italy )


Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and severe adverse effects related to cancer treatment. Unfortunately, although several agents and protocols have been proposed, no prophylactic strategies have yet to be proven useful. Therefore, new alternative therapies have been considered for CIPN prevention. Herbal medicine in Japan, called Kampo medicine, is derived from traditional Chinese medicine. Goshajinkigan (GJG) is a Kampo medicine, that is comprised of ten herbs. The aim of this work is to analyse the results of pre-clinical and clinical studies on the potential applications of GJG in CIPN prevention.

Welcome to JCIM! You are the number 2448 reader of this article!
Download Article:
[Full Text]      [PDF]      [Chinese]      [Previous]      [Next]      [This Issue]
Please cite this article as:
Cascella M, Muzio MR. Potential application of the Kampo medicine goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy. J Integr Med. 2017; 15(2): 77–87.
1Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity[J].Curr Opin Neurol, 2015, 28(5): 500–507.  .
2Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis[J].Pain, 2014, 155(12): 2461–2470.  .
3Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis[J].CA Cancer J Clin, 2013, 63(6): 419–437.  .
4Smith EM, Cohen JA, Pett MA, Beck SL. The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums[J].Cancer Nurs, 2010, 33(3): 173–183.  .
5Plasmati R, Pastorelli F, Cavo M, Petracci E, Zamagni E, Tosi P, Cangini D, Tacchetti P, Salvi F, Bartolomei I, Michelucci R, Tassinari CA. Neuropathy in multiple myeloma treated with thalidomide: a prospective study[J].Neurology, 2007, 69(6): 573–581.  .
6Cavaletti G, Beronio A, Reni L, Ghiglione E, Schenone A, Briani C, Zara G, Cocito D, Isoardo G, Ciaramitaro P, Plasmati R, Pastorelli F, Frigo M, Piatti M, Carpo M. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study[J].Neurology, 2004, 62(12): 2291–2293.  .
7Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature[J].Blood, 2008, 112(5): 1593–1599.  .
8Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update[J].Crit Rev Oncol Hematol, 2012, 82(1): 51–77.  .
9Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents[J].Curr Opin Neurol, 2007, 20(6): 719–725.  .
10Tanay MA, Armes J, Ream E. The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis. Eur J Cancer Care (Engl). 2016. Epub ahead of print.
11Schmidinger M, Budinsky AC, Wenzel C, Piribauer M, Brix R, Kautzky M, Oder W, Locker GJ, Zielinski CC, Steger GG. Glutathione in the prevention of cisplatin-induced toxicities: a prospectively randomized pilot trial in patients with head and neck cancer and non-small cell lung cancer[J].Wien Klin Wochenschr, 2000, 112(14): 617–623.  .
12Hilpert F, St?hle A, Tomé O, Burges A, Rossner D, Sp?the K, Heilmann V, Richter B, du Bois A; Arbeitsgemeinschaft Gyn?kologische Onkologoie (AGO) Ovarian Cancer Study Group. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group[J].Support Care Cancer, 2005, 13(10): 797–805.  .
13Kanat O, Evrensel T, Baran I, Coskun H, Zarifoglu M, Turan OF, Kurt E, Demiray M, Gonullu G, Manavoglu O. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study[J].Med Oncol, 2003, 20(3): 237–245.  .
14Lin PC, Lee MY, Wang WS, Yen CC, Chao TC, Hsiao LT, Yang MH, Chen PM, Lin KP, Chiou TJ. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data[J].Support Care Cancer, 2006, 14(5): 484–487.  .
15Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D, Kaye SB. Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin[J].Cancer Chemother Pharmacol, 1998, 41(2): 161–166.  .
16Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy[J].J Clin Oncol, 2013, 31(20): 2627–2633.  .
17Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, Smith DA, Berg AR, Stella PJ, Loprinzi CL. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial[J].Support Care Cancer, 2011, 19(11): 1769–1777.  .
18Ghoreishi Z, Esfahani A, Djazayeri A, Djalali M, Golestan B, Ayromlou H, Hashemzade S, Asghari Jafarabadi M, Montazeri V, Keshavarz SA, Darabi M. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial[J].BMC Cancer, 2012, 12: 355.  .
19Arrieta O, Hernandez-Pedro N, Fernandez-Gonzalez-Aragon MC, Saavedra-Perez D, Campos-Parra AD, Rios-Trejo MA, Ceron-Lizarraga T, Martinez-Barrera L, Pineda B, Ordonez G, Ortiz-Plata A, Granados-Soto V, Sotelo J. Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer[J].Neurology, 2011, 77(10): 987–995.  .
20Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance)[J].J Clin Oncol, 2014, 32(10): 997–1005.  .
21Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial[J].Ann Oncol, 2012, 23(1): 200–205.  .
22Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL; American Society of Clinical Oncology. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline[J].J Clin Oncol, 2014, 32(18): 1941–1967.  .
23Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, de Gramont A. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study[J].J Clin Oncol, 2006, 24(3): 394–400.  .
24Al Moundhri MS, Al-Salam S, Al Mahrouqee A, Beegam S, Ali BH. The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical, and histopathological studies[J].J Med Toxicol, 2013, 9(1): 25–33.  .
25Namvaran Abbas Abad A, Kayate Nouri MH, Gharjanie A, Tavakoli F. Effect of Matricaria chamomilla hydroalcoholic extract on cisplatin-induced neuropathy in mice[J].Chin J Nat Med, 2011, 9(2): 126–131.  .
26Park HJ, Lee HG, Kim YS, Lee JY, Jeon JP, Park C, Moon DE. Ginkgo biloba extract attenuates hyperalgesia in a rat model of vincristine-induced peripheral neuropathy[J].Anesth Analg, 2012, 115(5): 1228–1233.  .
27Lee JS, Kim YT, Jeon EK, Won HS, Cho YS, Ko YH. Effect of green tea extracts on oxaliplatin-induced peripheral neuropathy in rats[J].BMC Complement Altern Med, 2012, 12: 124.  .
28Satoh H. Pharmacological characteristics of Kampo medicine as a mixture of constituents and ingredients[J].J Integr Med, 2013, 11(1): 11–16.  .
29Brami C, Bao T, Deng G. Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: a systematic review[J].Crit Rev Oncol Hematol, 2016, 98: 325–334.  .
30Schroder S, Beckmann K, Franconi G, Meyer-Hamme G, Friedemann T, Greten HJ, Rostock M, Efferth T. Can medical herbs stimulate regeneration or neuroprotection and treat neuropathic pain in chemotherapy-induced peripheral neuropathy? Evid Based Complement Alternat Med. 2013; 2013: 423713.
31Ohnishi S, Takeda H. Herbal medicines for the treatment of cancer chemotherapy-induced side effects[J].Front Pharmacol, 2015, 6: 14.  .
32Watanabe K, Shimada A, Miyaki K, Hirakata A, Matsuoka K, Omae K, Takei I. Long-term effects of goshajinkigan in prevention of diabetic complications: a randomized open-labeled clinical trial[J].Evid Based Complement Alternat Med, 2014, 2014: 128726.  .
33Terasawa K. Evidence-based reconstruction of Kampo medicine: part-III—how should Kampo be evaluated? Evid Based Complement Alternat Med. 2004; 1(3): 219–222.
34Iwase S, Yamaguchi T, Miyaji T, Terawaki K, Inui A, Uezono Y. The clinical use of Kampo medicines (traditional Japanese herbal treatments) for controlling cancer patients’ symptoms in Japan: a national cross-sectional survey[J].BMC Complement Altern Med, 2012, 12: 222.  .
35European Commission. Medicinal products for human use. [2016-09-04]. https://ec.europa.eu/health/human-use/herbal-medicines/index_en.htm.
36Uno T, Ohsawa I, Tokudome M, Sato Y. Effects of goshajinkigan on insulin resistance in patients with type 2 diabetes[J].Diabetes Res Clin Pract, 2005, 69(2): 129–135.  .
37Higuchi H, Yamamoto S, Ushio S, Kawashiri T, Egashira N. Goshajinkigan reduces bortezomib-induced mechanical allodynia in rats: possible involvement of κ-opioid receptor[J].J Pharmacol Sci, 2015, 129(3): 196–199.  .
38Kitamura R, Andoh T, Fushimi H, Komatsu K, Shibahara N, Kuraishi Y. Involvement of descending monoaminergic systems in antiallodynic effect of goshajinkigan in oxaliplatin-treated mice[J].J Tradit Med, 2013, 30(4): 183–189.  .
39Yamada K, Suzuki E, Nakaki T, Watanabe S, Kanba S. Aconiti tuber increases plasma nitrite and nitrate levels in humans[J].J Ethnopharmacol, 2005, 96(1–2): 165–169.  .
40Imamura T, Ishizuka O, Aizawa N, Zhong C, Ogawa T, Nakayama T, Tanabe T, Nishizawa O. Go-sha-jinki-gan reduces transmitter proteins and sensory receptors associated with C fiber activation induced by acetic acid in rat urinary bladder[J].Neurourol Urodyn, 2008, 27(8): 832–837.  .
41Nakanishi M, Nakae A, Kishida Y, Baba K, Sakashita N, Shibata M, Yoshikawa H, Hagihara K. Go-sha-jinki-gan (GJG) ameliorates allodynia in chronic constriction injury-model mice via suppression of TNF-α expression in the spinal cord. Mol Pain. 2016; 12.
42Mizuno K, Kono T, Suzuki Y, Miyagi C, Omiya Y, Miyano K, Kase Y, Uezono Y. Goshajinkigan, a traditional Japanese medicine, prevents oxaliplatin-induced acute peripheral neuropathy by suppressing functional alteration of TRP channels in rat[J].J Pharmacol Sci, 2014, 125(1): 91–98.  .
43Nassini R, Gees M, Harrison S, De Siena G, Materazzi S, Moretto N, Failli P, Preti D, Marchetti N, Cavazzini A, Mancini F, Pedretti P, Nilius B, Patacchini R, Geppetti P. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation[J].Pain, 2011, 152(7): 1621–1631.  .
44Matsumura Y, Yokoyama Y, Hirakawa H, Shigeto T, Futagami M, Mizunuma H. The prophylactic effects of a traditional Japanese medicine, goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of action[J].Mol Pain, 2014, 10: 61.  .
45Kono T, Suzuki Y, Mizuno K, Miyagi C, Omiya Y, Sekine H, Mizuhara Y, Miyano K, Kase Y, Uezono Y. Preventive effect of oral goshajinkigan on chronic oxaliplatin-induced hypoesthesia in rats[J].Sci Rep, 2015, 5: 16078.  .
46Kamei J, Hayashi S, Miyata S. Effect of goshajinkigan on vincristine-induced painful neuropathy in mice[J].Jpn J Pharm Palliat Care Sci, 2008, 1(1): 19–24.  .
47Andoh T, Kato M, Kitamura R, Mizoguchi S, Uta D, Toume K, Komatsu K, Kuraishi Y. Prophylactic administration of an extract from Plantaginis Semen and its major component aucubin inhibits mechanical allodynia caused by paclitaxel in mice[J].J Tradit Complement Med, 2016, 6(3): 305–308.  .
48Andoh T, Kitamura R, Fushimi H, Komatsu K, Shibahara N, Kuraishi Y. Effects of goshajinkigan, hachimijiogan, and rokumigan on mechanical allodynia induced by paclitaxel in mice[J].J Tradit Complement Med, 2014, 4(4): 293–297.  .
49Mizuno K, Shibata K, Komatsu R, Omiya Y, Kase Y, Koizumi S. An effective therapeutic approach for oxaliplatin-induced peripheral neuropathy using a combination therapy with goshajinkigan and bushi. Cancer Biol Ther. 2016. Epub ahead of print.
50Zhou G, Tang L, Zhou X, Wang T, Kou Z, Wang Z. A review on phytochemistry and pharmacological activities of the processed lateral root of Aconitum carmichaelii Debeaux[J].J Ethnopharmacol, 2015, 160: 173–193.  .
51Suzuki Y, Goto K, Ishige A, Komatsu Y, Kamei J. Antinociceptive effect of goshajinkigan, a Kampo medicine, in streptozotocin-induced diabetic mice[J].Jpn J Pharmacol, 1999, 79(2): 169–175.  .
52Tai T, Akita Y, Kinoshita K, Koyama K, Takahashi K, Watanabe K. Anti-emetic principles of Poria cocos[J].Planta Med, 1995, 61(6): 527–530.  .
53Di Cesare Mannelli L, Zanardelli M, Failli P, Ghelardini C. Oxaliplatin-induced oxidative stress in nervous system-derived cellular models: could it correlate with in vivo neuropathy? Free Radic Biol Med. 2013; 61: 143–150.
54Bahar MA, Andoh T, Ogura K, Hayakawa Y, Saiki I, Kuraishi Y. Herbal medicine goshajinkigan prevents paclitaxel-induced mechanical allodynia without impairing anti-tumor activity of paclitaxel[J].Evid Based Complement Alternat Med, 2013, 2013: 849754.  .
55Ushio S, Egashira N, Sada H, Kawashiri T, Shirahama M, Masuguchi K, Oishi R. Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumor efficacy in rodents[J].Eur J Cancer, 2012, 48(9): 1407–1413.  .
56Chen M, May BH, Zhou IW, Sze DM, Xue CC, Zhang AL. Oxaliplatin-based chemotherapy combined with traditional medicines for neutropenia in colorectal cancer: a meta-analysis of the contributions of specific plants[J].Crit Rev Oncol Hematol, 2016, 105: 18–34.  .
57Shindo Y, Tenma K, Imano H, Hibino M, Yoshino K, Nakamura M. Reduction of oxaliplatin-related neurotoxicity by goshajinkigan[J].Gan To Kagaku Ryoho, 2008, 35(5): 863–865.  .
58Kaku H, Kumagai S, Onoue H, Takada A, Shoji T, Miura F, Yoshizaki A, Sato S, Kigawa J, Arai T, Tsunoda S, Tominaga E, Aoki D, Sugiyama T. Objective evaluation of the alleviating effects of goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: a multicenter collaborative study. Exp Ther Med. 2012; 3(1): 60–65.
59Abe H, Kawai Y, Mori T, Tomida K, Kubota Y, Umeda T, Tani T. he Kampo medicine goshajinkigan prevents neuropathy in breast cancer patients treated with docetaxel.[J].Asian Pac J Cancer Prev, 2013, 32(7): 2545–2550.  .
60Nishioka M, Shimada M, Kurita N, Iwata T, Morimoto S, Yoshikawa K, Higashijima J, Miyatani T, Kono T. The Kampo medicine, goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen[J].Int J Clin Oncol, 2011, 16(4): 322–327.  .
61Hosokawa A, Ogawa K, Ando T, Suzuki N, Ueda A, Kajiura S, Kobayashi Y, Tsukioka Y, Horikawa N, Yabushita K, Fukuoka J, Sugiyama T. Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study. Anticancer Res. 2012; 32(7): 2545–2550
62Yoshida N, Hosokawa T, Ishikawa T, Yagi N, Kokura S, Naito Y, Nakanishi M, Kokuba Y, Otsuji E, Kuroboshi H, Taniwaki M, Taguchi T, Hosoi H, Nakamura T, Miki T. Efficacy of goshajinkigan for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients. J Oncol. 2013; 2013: 139740.
63Kono T, Hata T, Morita S, Munemoto Y, Matsui T, Kojima H, Takemoto H, Fukunaga M, Nagata N, Shimada M, Sakamoto J, Mishima H. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, doubleblind, placebocontrolled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy.[J].Cancer Chemother Pharmacol, 2013, 72(6): 1283–1290.  .
63Kono T, Hata T, Morita S, Munemoto Y, Matsui T, Kojima H, Takemoto H, Fukunaga M, Nagata N, Shimada M, Sakamoto J, Mishima H.. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, doubleblind, placebocontrolled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. Cancer Chemother Pharmacol. .[J].2013, 72(6): 1283–1290.  .
64Oki E, Emi Y, Kojima H, Higashijima J, Kato T, Miyake Y, Kon M, Ogata Y, Takahashi K, Ishida H, Saeki H, Sakaguchi Y, Yamanaka T, Kono T, Tomita N, Baba H, Shirabe K, Kakeji Y, Maehara Y.. Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol. .[J].2015, 20(4): 767–775.  .

 Home | Current Issue | Past Issues | Search | CollectionsRSS | PDA Services | FAQ | SHCIM Online | Chinese
Copyright © 2003-2012 by JCIM Press. All rights reserved. ISSN 1672-1977